Tatsuya Tominaga Selected Research

Bone Morphogenetic Protein 4

1/2019	All-trans retinoic acid suppresses bone morphogenetic protein 4 in mouse diabetic nephropathy through a unique retinoic acid response element.
8/2015	Bone Morphogenetic Protein 4 and Smad1 Mediate Extracellular Matrix Production in the Development of Diabetic Nephropathy.
6/2012	Scleraxis modulates bone morphogenetic protein 4 (BMP4)-Smad1 protein-smooth muscle α-actin (SMA) signal transduction in diabetic nephropathy.
6/2011	Activation of bone morphogenetic protein 4 signaling leads to glomerulosclerosis that mimics diabetic nephropathy.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Tatsuya Tominaga Research Topics

Disease

12	Diabetic Nephropathies (Diabetic Nephropathy) 01/2019 - 06/2008
3	Glomerulonephritis 01/2013 - 01/2010
2	Kidney Diseases (Kidney Disease) 11/2021 - 01/2019
2	Insulin Resistance 12/2019 - 10/2019
2	Chronic Kidney Failure (Chronic Renal Failure) 01/2019 - 01/2018
2	Wounds and Injuries (Trauma) 01/2019 - 01/2010
2	IGA Glomerulonephritis (IGA Nephropathy) 10/2017 - 01/2013
1	Metabolic Syndrome (Dysmetabolic Syndrome X) 10/2019
1	Diabetes Complications 01/2019
1	Albuminuria 10/2017
1	Nephritis 10/2017
1	Tuberous Sclerosis (Bourneville's Disease) 10/2017
1	Immunoglobulin Light-chain Amyloidosis 01/2017
1	Amyloid Plaque 01/2017
1	Amyloidosis 01/2017
1	Obesity 01/2016
1	Vascular Calcification 12/2013
1	Hyperlipidemias (Hyperlipidemia) 10/2009

Drug/Important Bio-Agent (IBA)

6	Proteins (Proteins, Gene)FDA Link 01/2019 - 09/2011
4	Bone Morphogenetic Protein 4IBA 01/2019 - 06/2011
2	Apolipoprotein L1IBA 12/2019 - 10/2019
2	Biomarkers (Surrogate Marker)IBA 01/2018 - 11/2008
2	AlbuminsIBA 01/2018 - 10/2009
2	Mechanistic Target of Rapamycin Complex 1IBA 10/2017 - 01/2016
1	CytokinesIBA 11/2021
1	oxidized low density lipoproteinIBA 10/2019
1	HDL CholesterolIBA 10/2019
1	Lipoproteins (Lipoprotein)IBA 10/2019
1	RetinoidsIBA 01/2019
1	Tretinoin (Retinoic Acid)FDA LinkGeneric 01/2019
1	Collagen Type IV (Type IV Collagen)IBA 01/2018
1	Immunoglobulin G (IgG)IBA 01/2018
1	Ribosomal Protein S6IBA 10/2017
1	CollagenIBA 10/2017
1	Phosphotransferases (Kinase)IBA 10/2017
1	Tamoxifen FDA LinkGeneric 10/2017
1	TOR Serine-Threonine KinasesIBA 10/2017
1	Potassium PermanganateIBA 01/2017
1	Congo RedIBA 01/2017
1	Amyloid (Amyloid Fibrils)IBA 01/2017
1	DAPIIBA 01/2017
1	Inositol OxygenaseIBA 01/2016
1	Fatty Acids (Saturated Fatty Acids)IBA 01/2016
1	Matrix Gla ProteinIBA 12/2013
1	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 01/2013
1	Monoclonal AntibodiesIBA 03/2011
1	Platelet-Derived Growth FactorIBA 03/2011
1	Transcription Factors (Transcription Factor)IBA 09/2010
1	Activin Receptors (Activin Receptor)IBA 09/2010
1	Glycoproteins (Glycoprotein)IBA 01/2010
1	CreatinineIBA 10/2009
1	Angiotensin IIIBA 11/2008
1	Angiotensin II Type 1 Receptor BlockersIBA 06/2008

Therapy/Procedure

1	Kidney Transplantation 01/2019
1	Renal Dialysis (Hemodialysis) 12/2013
1	Intravenous Injections 03/2011